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Hodgkin’s disease (HD) and non-Hodgkin’s lymphoma (NHL)
represent approximately 3–5% of all reported malignancies.
Whilst the incidence of HD shows a general downwards trend, the
overall incidence of NHL is gradually increasing by an estimated
3% per annum. A typical UK health authority (population
500 000) should expect to see between 60 and 70 new cases of
NHL and 8–10 new cases of HD each year. Although patients with
relapsed disease have historically had a very poor prognosis, new
treatment strategies can now cure approximately 40 – 50% of suit-
able patients.
The use of high dose chemotherapy (HDC) initially supported
by autologous bone marrow transplantation (ABMT) and, more
recently, peripheral blood stem cells (PBSC), has rapidly become a
routine treatment for relapsed lymphoma patients. In studies of
relapsed HD patients, long-term survival rates of 50–65% have
been reported using various HDC regimens (Reece et al, 1991;
Bierman et al, 1993; Chopra et al, 1993; Goldstone et al, 1993).
Similar results have been shown for relapsed high/intermediate
grade NHL patients (Philip et al, 1991, 1995; Salzman et al, 1997).
In a recent review (Beard et al, 1998) we considered the role and
cost-effectiveness of HDC in the treatment of lymphoma for the
Trent Institute Working Group on Acute Purchasing (TIWGAP), a
regional body established to consider evidence of clinical and
cost-effectiveness for new drugs and interventions. We present our
pharmacoeconomic findings, and draw on the key messages of
cost-effectiveness.
METHODS
We focused specifically on patients with relapsed HD and relapsed
high/intermediate grade NHL, as these are the areas where clinical
evidence of efficacy is most convincing.
A systematic literature search of Medline, Embase and BIDS
Science Citation Index identifying all trials of HDC in lymphoma
was carried out, to include all trials up until end January 1998.
Results were cross-referenced against the references used within
the ongoing HTA Systematic Review (now published – Johnson
et al, 1998). Although randomized control trials (RCTs) were
targeted as a ‘gold standard’, there is very little RCT evidence
available in this area and evidence from large peer-reviewed case
series was also considered. As curative therapy was the basis of
HDC treatment the primary outcome measure of this analysis was
cost per life year gained (LYG). In estimating the survival benefits
of HDC against those of standard salvage chemotherapy, we
adopted a methodology based on area under the curve (AUC)
estimation, where the AUC was taken directly from the published
Kaplan–Meier graphs. This approach allows the experience of the
whole trial arm to be acknowledged rather than using a single
point estimate, such as the median survival statistic.
As trial data suggest a longer term survival for HDC we
included a consideration of potential longer term benefits, i.e.
those lying beyond the trial period, based on an extrapolation of
published survival data. We adopted a conservative approach in
terms of interpretation of clinical benefits and inclusion of treat-
ment costs.
Guidelines for costing chemotherapy have been issued by the
National Health Service Executive (NHS Management Executive,
1993). Briefly, these costs are split into fixed, semi-fixed and vari-
able costs and include a portion of all costs incurred in running a
hospital, on a pro-rata basis. The costs of standard chemotherapy,
salvage chemotherapy and high dose therapy at this institution
have previously been estimated (Hancock et al, 1995). However,
these costs are unique to this unit and depend on specific case mix,
activity, specialist facilities etc. Whilst they are very useful for the
purpose of contracting, they are not easily transferable to another
unit. A more durable assessment of cost can be gained simply from
drug acquisition costs and time in hospital. This can then be
supplemented with specific costs applicable to that unit. The Out
of Area Treatment (OATS) cost for high dose therapy at this unit is
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chemotherapy is £960, and the total cost rises to £1700 if one
assumes a 50% chance of neutropenic sepsis. This cost includes 5
days of antibiotics, 2 unit blood transfusion, 5 units of platelets,
antifungal therapy etc. We have based our cost for standard dose
salvage therapy on these costs although salvage treatment for NHL
tends to be individualized and is likely to be significantly more
expensive than standard first-line CHOP chemotherapy. The mean
cost of palliative therapy for Hodgkin’s disease, including time
spent in hospital, antibiotic usage etc. has been calculated at £9500
for this unit. The costs above do not include the costs borne by
palliative care, primary care etc.
It is likely that the costs for standard salvage therapy are an
underestimate, with the result that high dose chemotherapy will
look disproportionately more expensive when compared to
standard therapy. The marginal cost of HDC is estimated to be
approximately £13 900, based on first-line therapy alone.
A sensitivity analysis was conducted in order to explore the
potential influence of variance in both treatment costs and bene-
fits. We allowed the marginal cost of HDC to vary between
£10 000 and £20 000 to consider the influence of including
salvage therapy costs and the potential regional variations in HDC
costs. We also explored a ± 50% variation around the marginal
clinical benefits of HDC.
RESULTS
Marginal benefit of HDC in relapsed HD patients
The British National Lymphoma Investigation (Linch et al, 1993)
showed improved overall response rates for BEAM+ABMT
versus mini-BEAM (74% vs 60%, P > 0.1) and increased 3 years
actuarial event-free survival (53% vs 10%, P < 0.05). Overall, 15
patients remained alive after 34 months follow-up, compared to 11
in mini-BEAM arm (P = 0.318). This trial failed to reach the
recruitment target as patients were refusing randomization in
favour of HDC.
HDC was estimated to provide a marginal survival benefit of 10
months per patient, with the plateau of the survival curve indi-
cating long-term survival with likely prolonged benefits beyond
the trial end point. Marginal survival benefits and corresponding
cost per LYG figures, for trial data alone and time periods at 5, 10,
and 20 years beyond the end of the trial data are shown in Table 1.
The majority of the impact is apparent in the first 5 years beyond
the trial end point.
In addition, we compared data from the larger HDC case series
(Chopra et al, 1993) with outcomes of conventionally treated HD
patients, as suggested by the National Cancer institute (NCI) series
(Longo et al, 1992). This provided a similar magnitude of benefit
for HDC, with marginal survival benefit at 11 months. A recent
randomized study from the EBMT comparing standard therapy
with HDC in relapsed HD which closed early due to poor accrual,
showed no survival advantage for the HDC arm (Schmitz et al,
1999). However, this was because the majority of patients who
relapsed after standard therapy were then salvaged with HDC. Full
details are not yet available but the authors concluded that HDC is
still the treatment of choice for HD in first relapse.
Marginal benefits of HDC in relapsed NHL patients
The PARMA group (Philip et al, 1995) showed an initial response
rate of 84% after HDC and 44% after standard salvage treatment in
relapsed NHL patients. At 5 years the event-free survival was
significantly greater in the HDC arm (46% vs 12%, P = 0.001) and
overall survival was also superior (53% vs 32%). The marginal
survival benefit was calculated as 13 months (1.1 LYG) per
patient, in favour of HDC, and again a forward projection of bene-
fits was taken beyond the original trial period (Table 1). Recently
updated trial data (Philip et al, 1998), taken over an 8-year follow-
up period, suggests that patient survival benefits are sustained and
significant differences remain over the long-term. This provides
further support to our original projection of benefits beyond the
initial trial period. The 8-year event-free survival (36% vs 11%,
P < 0.002) and overall survival (47% vs 27%, P < 0.042) figures
correspond to an estimated marginal survival benefit of 18 months
(1.5 LYG) and a cost per LYG of £9267 (Table 1).
Sensitivity analysis
The results of the sensitivity analysis are summarized in graphical
form, allowing different combinations of costs and benefits to be
considered as required (Figures 1 and 2). Each graph shows three
separate series, corresponding to different levels of clinical benefit
and representing a level of cost-effectiveness, tracking cost per life
year values against the marginal cost of HDC. If the benefits are
assumed to be equal to those seen within the trial the cost-
effectiveness of HDC in both NHL and HD remains under £25 000
per LYG, even when the marginal cost of HDC is increased to
£20 000.
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Table 1 High dose chemotherapy survival benefits and cost per LYG
Hodgkin’s disease Non-Hodgkin’s lymphoma
BNLI Trial PARMA Trial
Forward Projection Survival LYG Cost per Survival LYG Cost per
of Benefit LYG benefit LYG
Trial Data (mths) (mths)
Initial trial data only 10 0.8 £17 375 13 1.1 £12 636
5 years extended 28 2.3 £6 043 27 2.3 £6043
10 years extended 45 3.8 £3 658 40 3.3 £4212
20 years extended 78 6.5 £2 138 66 5.5 £2527
Long-term trial n/a n/a n/a 18 1.5 £9267
follow-up data
(2 years extended)DISCUSSION
The strength of observational study evidence strongly supports the
use of HDC in relapsed HD and relapsed high/intermediate grade
NHL. There is little RCT evidence available and further trials are
unlikely to take place due to recruitment difficulties for the
standard therapy arm. The BNLI trial did not reach a statistically
significant survival advantage as the trial was stopped early. The
EBMT trial was essentially a study comparing early with late HDC
in relapsed Hodgkin’s disease. Recently revised EBMT guidelines
provide a useful framework within which to consider the role of
HDC for treatment of HD and NHL (Goldman et al, 1998).
The cost-effectiveness arguments for the use of HDC in relapsed
NHL and relapsed HD patients are strong, even under sensitivity
analysis involving both costs and benefits. The cost-effectiveness
ratios, at £12 636 and £17 375 respectively, are certainly compa-
rable with similarly supported therapies and fall under generally
accepted UK cost-effectiveness thresholds of around £20 000 per
LYG (Stevens et al, 1995). Even using these conservative cost esti-
mates, if 5-year projected benefits are included the cost per LYG
figures are reduced by around 50%.
The actual marginal cost of HDC may be significantly lower
than that used in our analysis as the high initial costs of HDC
would be partially offset by the reduced likelihood of further
chemotherapy following relapse. Patients with high grade NHL
who relapse tend to have aggressive disease and do not survive
very long. Patients with relapsed HD may exhibit a chronic
relapsing remitting condition requiring regular treatment and
supportive care, but long-term survival is unusual. Furthermore,
this analysis has not taken into account difference in the quality of
life between patients cured of their lymphoma and those receiving
palliative therapy for incurable disease.
Cost-effectiveness analyses of new treatments are an integral
part of the move towards evidence-based purchasing for all health
services, including oncology. The establishment of the National
Institute for Clinical Excellence (NICE) has formalized the efforts
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Figure 1 Cost-effectiveness sensitivity in NHL patients
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Figure 2 Cost-effectiveness sensitivity in HD patientsof TIWGAP and similar regional development and evaluation
bodies currently conducting cost-effectiveness analysis for
the Inter-DEC (Department of Health, 1998). Clinicians and
purchasers alike need to remain aware of cost-effectiveness issues
and empower themselves in such an evidence-based environment.
High dose chemotherapy in relapsed HD and NHL is both a
clinically effective and cost-effective treatment strategy.
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